Monograph Title Sort descending | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
<724> DRUG RELEASE | GENERAL DRUG RELEASE STANDARDS | USP41–NF36 | 6471 | 27-Apr-2018 | 1-May-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Figure 5: Change O to: Ø |
<733> LOSS ON IGNITION | INTRODUCTION | USP43–NF38 | Online | 30-Oct-2020 | 1-Nov-2020 | NA | NA | In paragraph 3: Change Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator to room temperature before weighing. to: Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator to room… Read More |
<795> PHARMACEUTICAL COMPOUNDING— NONSTERILE PREPARATIONS | STABILITY CRITERIA AND BEYOND-USE DATING/General Guidelines for Assigning Beyond-Use Dates | Revision Bulletin (Official January 01, 2014) | Online | 28-Mar-2014 | 1-Apr-2014 | Second Supplement to USP37–NF32 | Second Supplement to USP37–NF32 | Line 7 of Paragraph 1: Change (see the General Notices and Requirements, Preservation, Packaging, Storage, and Labeling) to: (see <659>) |
<795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS | DEFINITIONS | USP37–NF32 | 403 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Beyond-Use Date (BUD): Change The date after which a compounded preparation should not to be used; to: The date after which a compounded preparation shall not be used; |
<795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS | COMPOUNDING FACILITIES | Revision Bulletin (Official January 01, 2014) | Online | 28-Mar-2014 | 1-Apr-2014 | Second Supplement to USP37–NF32 | Second Supplement to USP37–NF32 | Line 4 of Paragraph 4: Change (see the General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity; to: (see Packaging and Storage Requirements <659>; |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | APPENDICES/Appendix 3: Types of Biological Safety Cabinets/Class II | First Supplement to USP39–NF34 | 7721 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 5 of Type A1 (formerly, Type A): Change radionucleotides to: radionuclides AND Line 5 of Type A2 (formerly, Type B3): Change radionucleotides to: radionuclides AND Line 5 of Type B1: Change radionucleotides to: radionuclides … Read More |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | 5. FACILITIES AND ENGINEERING CONTROLS/5.4 Containment Supplemental Engineering Controls | First Supplement to USP40–NF35 | Online | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 5 of paragraph 1: Change containment reduction. to: contamination reduction. |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | 7. PERSONAL PROTECTIVE EQUIPMENT | First Supplement to USP40–NF35 | Online | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 2 of paragraph 2: Change antineoplastic HDs. to: injectable antineoplastic HDs. |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | 5. FACILITIES AND ENGINEERING CONTROLS/5.3 Compounding | First Supplement to USP39–NF34 | 7721 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | First bullet in second paragraph: Change • Be externally vented through high-efficiency particulate air (HEPA) filtration to: • Be externally vented |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | REFERENCES | First Supplement to USP39–NF34 | 7721 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 2 of first reference: Delete http://www.acoem.org/Reproductive_Developmental_Hazard_Management.aspx. AND Line 2 of second reference: Delete … Read More |
<800> HAZARDOUS DRUGS - HANDLING IN HEALTHCARE SETTINGS | REFERENCES | Revision Bulletin (Official December 01, 2017) | Online | 31-Aug-2018 | 1-Sep-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Reference 37: Delete http://www.osha.gov/Publications/osha3151.html. |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | APPENDIX 1. FORMULAS FOR MANUAL CALCULATIONS OF REGRESSION AND SAMPLE CONCENTRATION | USP38–NF33 | 133 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 19: Change b = [(4 × 17.222) + (2 × 16.511) − (2 × 14.989) − (4 × 14.020)]/{5[ln(7.81)] − ln(3.2)} = 3.551 to: b = [(4 × 17.222) + (2 × 16.511) − (2 × 14.989) − (4 × 14.020)]/{5[ln(7.81) − ln(3.2)]} = 3.551 |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | APPENDICES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In two instances in Appendix 1 equations: Change 14.020 to: 14.022 |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | Turbidimetric Method | USP36–NF31 | 76 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 9 of Paragraph 2 of Analysis: Change or a water bath maintained at the temperature specified in Table 8 and for the time specified in Table 11. to: or a water bath maintained at 36.0° –37.5° for the time specified in Table 11. |
<81> Antibiotics—Microbial Assays | Turbidimetric Method | USP35–NF30 | 74 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 8 of Analysis: Change Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see Table 8) but no antibiotic. to: Include in each rack 1–2 control tubes containing 1 mL of the test diluent (see Table 7) but no antibiotic. |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | CALCULATIONS/Turbidimetric Assay/Sample Data | USP40–NF35 | 143 | 23-Feb-2018 | 1-Mar-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Second equation in Step 1: Change 0.0125 = to: 0.0062 = AND Third equation in Step 1: Change 0.0325 = to: 0.0322 = |
<852> ATOMIC ABSORPTION SPECTROSCOPY | VALIDATION AND VERIFICATION/Precision/Intermediate Precision | USP38–NF33 | 649 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 3: Change As a minimum, the analytical procedure should be assessed by performing the repeatability test in any of the conditions previously mentioned (totaling 12 measurements). to: As a minimum, the analytical procedure should be assessed by performing the repeatability test in… Read More |
<855> NEPHELOMETRY AND TURBIDIMETRY | 4. INSTRUMENTATION | USP42–NF37 | 7059 | 26-Apr-2019 | 1-May-2019 | NA | NA | In paragraph 2: Change silicone diodes to: silicon diodes |
<855> NEPHELOMETRY AND TURBIDIMETRY | 5. FORMAZIN TURBIDITY STANDARDS | USP42–NF37 | 7059 | 26-Apr-2019 | 1-May-2019 | NA | NA | In paragraph 1: Change IUPAC Compendium of Chemical Technology, to: IUPAC Compendium of Chemical Terminology, |
<856> NEAR-INFRARED SPECTROSCOPY | 4. VALIDATION AND VERIFICATION | USP43–NF38 | 7161 | 24-Apr-2020 | 1-May-2020 | NA | NA | In 4.1 Validation/4.1.1 Accuracy/Validation criteria/Criteria 1: Change Suitable agreement between SEP to: Suitable agreement between the standard error of prediction (SEP) |
<857> ULTRAVIOLET-VISIBLE SPECTROSCOPY | QUALIFICATION OF UV-VIS SPECTROMETERS | Second Supplement to USP42–NF37 | 9570 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In all instances in Table 4: Change < to: ≤ AND In Control of Photometric Response/Acidic Nicotinic Acid Solutions in 0.1 N Hydrochloric Acid/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy… Read More |
<871> SUTURES--NEEDLE ATTACHMENT | PROCEDURE | USPNF Online | Online | 29-Jul-2022 | 1-Aug-2022 | NA | NA | In Removable Needle Attachment: Change For USP sizes 5-0 through 2-0, to: For USP sizes 5-0 through 2, |
<915> MEASUREMENT OF STRUCTURAL STRENGTH OF SEMISOLIDS BY PENETROMETRY | APPARATUS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Figure 2: Change 66±0.25 Ø to: 65±0.25 Ø |
N-Benzoyl-L-arginine Ethyl Ester Hydrochloride | REAGENT SPECIFICATIONS | USPNF Online | Online | 30-Sep-2022 | 1-Dec-2022 | NA | NA | Change Crystallized Trypsin (USP Monograph). to: Trypsin (USP Monograph). |
ABIRATERONE ACETATE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 3 | Revision Bulletin (Official November 19, 2019) | Online | 26-Jun-2020 | 1-Jul-2020 | NA | NA | In Analysis: Change rU = peak response of abiratrone acetate from the Sample solution rS = peak response of abiratrone acetate from the Standard solution to: rU = peak… Read More |
ACAMPROSATE CALCIUM | IMPURITIES/Limit of Acamprosate Related Compound A | First Supplement to USP41–NF36 | 8263 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change CS = concentration of USP Acamprosate Calcium Related Compound A RS in the Standard solution (µg/mL) to: CS = concentration of USP Acamprosate Related… Read More |
ACARBOSE | IMPURITIES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In Chromatographic Purity/Analysis: Change Result = (rU/rA) × (1/F) × 100 to: Result = (rU/rA) × (1/F) |
ACARBOSE TABLETS | IDENTIFICATION/B. | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Change The spectrum obtained from the Sample solution shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm–1. to: The spectrum obtained from the sample preparation shows IR maxima in the regions of 3500–3200… Read More |
ACESULFAME POTASSIUM | IMPURITIES/Limit of Fluoride | USP35–NF30 | 1680 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 25 of Analysis: Change C = concentration of fluoride in the Sample solution, from the standard curve (mg/mL) to: C = concentration of fluoride in the Sample solution, from the standard curve (µg/mL) |
ACETAMINOPHEN AND CODEINE PHOSPHATE CAPSULES | PERFORMANCE TESTS | First Supplement to USP40–NF35 | 8201 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Dissolution <711>/Analysis:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the Calculate statement of Uniformity of Dosage Units <905>/Procedure for content… Read More |
ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS | PERFORMANCE TESTS | First Supplement to USP40–NF35 | 8202 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Dissolution <711>/Analysis:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the second Calculate statement in Uniformity of Dosage Units <905>/Procedure for… Read More |
ACETAMINOPHEN ORAL SUSPENSION | IMPURITIES/Organic Impurities | Revision Bulletin (Official August 01, 2018) | Online | 28-Sep-2018 | 1-Oct-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | This erratum applies to the new USP-NF ONLINE platform only. Change Solution B: 0.2% trifluoroacetic acid in water to: Solution B: 0.2% trifluoroacetic acid in acetonitrile |
ACETAMINOPHEN ORAL SUSPENSION | ASSAY | Second Supplement to USP41–NF36 | Online | 28-Jun-2019 | 1-Jul-2019 | NA | NA | In the first Procedure: Change 90.0%–110.0%▲(Postponed on 1-Aug-2018) to: 90.0%–110.0%▲(RB 1-Aug-2018) |
ACETAMINOPHEN SUPPOSITORIES | ASSAY/Procedure | USP37–NF32 | 1567 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6 of Sample stock solution: Change add 30 mL of hexane, to: add 30 mL of solvent hexane, AND Line 10 of Sample stock solution: Change wash the hexane to: wash the solvent hexane |
ACETAMINOPHEN TABLETS | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 24-Sep-2021 | 1-Oct-2021 | NA | NA | In Chromatographic system/Detector: Change UV 272 nm. For Identification B, use a diode array detector in the range of 200–400 nm. to: UV 272 nm |
ACETAZOLAMIDE FOR INJECTION | ASSAY | USP35–NF30 | 2063 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 19: Change 25C(AU/AS) to: 250C(AU/AS) |
ACETYLCYSTEINE SOLUTION | ASSAY/Procedure | USP40–NF35 | 2586 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of Sample solution: Change Standard stock solution to: Sample stock solution |
ACETYLTRIBUTYL CITRATE | IDENTIFICATION/B. | USP36–NF31 | 1869 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change USP Acetyltriethyl Citrate RS to: USP Acetyltributyl Citrate RS |
ACYCLOVIR | ASSAY/Procedure | USPNF Online | Online | 29-Apr-2022 | 1-May-2023 | NA | NA | In the Sample solution: Change 0.1 N sodium hydroxide to: 0.01 N sodium hydroxide |
ACYCLOVIR FOR INJECTION | IMPURITIES/Procedure | USPNF Online | Online | 25-Mar-2022 | 1-Apr-2022 | NA | NA | In Standard solution A: Change 0.5 μg/mL of Acyclovir standard solution in Solution A to: 0.5 μg/mL of USP Acyclovir RS from Acyclovir standard solution in Solution A AND In Standard solution B:… Read More |
ADAPALENE | IMPURITIES/Residual Solvent: Limit of Triethylamine | Revision Bulletin (Official December 01, 2012) | Online | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Diluent: Change Dimethyl sulfoxide and 1 N sodium hydroxide solution (4:1) to: Dimethyl sulfoxide AND Line 1 of Standard solution: Change 3.2 μg/mL of USP Triethylamine RS in Diluent to: 4.0 μg/mL of USP Triethylamine RS in Diluent.… Read More |
ADAPALENE GEL | ASSAY/Procedure | First Supplement to USP39–NF34 | 7983 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 5 of Sample stock solution: Change Cool to room temperature and dilute with Diluent to volume. to: Cool to room temperature and dilute with Mobile phase to volume. |
ADENINE | CHEMICAL INFORMATION | USP39–NF34 | 2346 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2: Change 1H-Purin-6-amine; to: 9H-Purin-6-amine; |
ADENOSINE | IDENTIFICATION/Infrared Absorption <197M> | USP35–NF30 | 2079 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 1: Delete NMT 0.1% |
ADIPIC ACID | IMPURITIES/Related Substances | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | NA | In Table 2: Change Pimelic acid 1.21 0.91 Valeric acid 1.21 0.91 to: Pimelic acid 1.21 0.91 Valeric acid 1.46 0.88 |
ALBUTEROL SULFATE | Chromatographic purity | USP36–NF31 | 2352 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Change It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution. to… Read More |
ALCOHOL IN DEXTROSE INJECTION | ASSAY/Dextrose | USP37–NF32 | 1637 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 15 of Analysis: Change A = length of the polarimeter tube (mm) to: A = 100 mm divided by the length of the polarimeter tube (mm) |
ALCOHOLOMETRIC TABLE | INTRODUCTION | USPNF 2021 ISSUE 3 | Online | 27-Aug-2021 | 1-Dec-2021 | NA | NA | Change Similarly, a specific gravity value of 0.8092 in column 1 corresponds to a solution that contains 95% alcohol by weight or 92.42% alcohol v/v. to: Similarly, a specific gravity value of 0.8092 in column 1 corresponds to a solution that… Read More |
ALFADEX | CHEMICAL INFORMATION | USP42–NF37 | 5561 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | Change 972.84 to: 972.85 |
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 29-Oct-2021 | 1-Nov-2021 | NA | NA | In Analysis: Change rS = peak response of alfuzosin from the Sample solution to: rS = peak response of alfuzosin from the Standard solution |